Categories: NewsPharmaceutical

Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release second quarter 2023 financial results on Thursday, August 3, 2023, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-929-201-5912.

A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.

About Assertio
Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.

Investor Contact
Matt Kreps
Darrow Associates Investor Relations
+1-214-597-8200
mkreps@darrowir.com  

Staff

Recent Posts

Smart Textiles Market worth $5.56 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The smart textiles market is projected to grow…

1 hour ago

Flow Cytometry Market worth US$9.85 billion in 2033 with 8.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87…

1 hour ago

Avantor® Reiterates Shareholder Value Creation Focus

Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to…

1 hour ago

Nordic and CLEAR partner to offer healthcare organizations a seamless, secure way to manage EHR accounts

MADISON, Wis., Aug. 11, 2025 /PRNewswire/ -- Nordic®, a global health and technology consulting company,…

1 hour ago

Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals,…

1 hour ago

EVERISE STRENGTHENS LEADERSHIP TEAM WITH CHIEF REVENUE OFFICER AND CHIEF FINANCIAL OFFICER APPOINTMENTS

PLANTATION, Fla., Aug. 11, 2025 /PRNewswire/ -- Everise, a global leader in transforming customer experiences,…

1 hour ago